Fibrates and coronary risk reduction.

Steiner G.

Atherosclerosis. 2005 Oct;182(2):199-207. doi: 10.1016/j.atherosclerosis.2005.04.002.

Many medications are currently available to correct lipoprotein abnormalities when lifestyle measures alone are not sufficient. No single agent or class of agents is able to correct all of the lipoprotein abnormalities. This paper reviews the role of one class, the fibrates, in the management of lipid disorders and summarizes the clinical trial information relating to their impact on coronary artery disease.

PMID: 15894321

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.